Metoperil AM 25 Tablet is a fixed-dose combination of two antihypertensive agents: Metoprolol Succinate, a cardioselective beta-1 blocker, and Amlodipine, a long-acting calcium channel blocker. This dual-therapy formulation is indicated for the effective management of hypertension (high blood pressure) and certain heart-related conditions such as angina pectoris and stable coronary artery disease.
Metoprolol Succinate works by selectively blocking beta-1 adrenergic receptors in the heart, leading to a reduction in heart rate, cardiac output, and blood pressure. It also helps reduce the workload on the heart, making it beneficial for patients with a history of myocardial infarction or chronic heart failure. Its extended-release formulation ensures stable plasma concentrations over a 24-hour period, offering consistent blood pressure control with once-daily dosing.
Amlodipine, on the other hand, inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in vasodilation and a subsequent decrease in peripheral vascular resistance. This mechanism not only lowers blood pressure but also helps relieve angina by improving blood flow to the heart muscle.
The combination of Metoprolol and Amlodipine in Metoperil AM 25 offers a synergistic effect—while Metoprolol controls the heart rate and cardiac output, Amlodipine targets vascular resistance. This dual mechanism makes the product highly effective in patients whose blood pressure is inadequately controlled on monotherapy or who require combination therapy for optimal cardiovascular risk reduction.
Metoperil AM 25 Tablet falls under the Hypertension/Blood Pressure and Cardiovascular therapeutic categories. It may also be classified under General medicines due to its widespread use in primary care settings.